Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

Appendix B: Panel Roster and Financial Disclosures

PCP

Last Updated: August 1, 2019; Last Reviewed: August 1, 2019

Pneumocystis Pneumonia
Member Financial Disclosure
Company Relationship
Crothers, Kristina Yale University School of Medicine American Lung Association Research Support
National Institutes of Health Research Support
Furrer, Hansjakob Universitatsspital Bern, Switzerland Association contre le VIH et autres infections tranmissibles Research Support
Gilead Research Support
Swiss HIV Research Foundation Research Support
Swiss National Science Foundation Research Support
Helweg-Larsen, Jannik Rigshospitalet, Copenhagen University, Denmark None N/A
Huang, Laurence University of California, San Francisco None N/A
Kalapila, Aley Emory University None N/A
Kovacs, Joe* National Institutes of Health Matinas BioPharma Research Support
Merck Research Support
Miller, Robert
University College London, England
British HIV Association Research Support
Gilead Honoraria, Speaker's Bureau
Morris, Alison
University of Pittsburgh Medical School
Gilead Research Support
* Group Lead

Note: Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.

Download Guidelines